香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公司謹此宣佈聯交所已確認封女士符合上市規則第3.28及8.17條下本公司之公司 秘書資格。此外，為維持高標準企業管治及確保及時有效遵守適用法律法規，儘管 封女士符合上市規則第3.28及8.17條下本公司之公司秘書資格，本公司將繼續聘請 李女士（居於香港）擔任聯席公司秘書。 承董事會命 醫渡科技有限公司 執行董事兼董事長 宮盈盈 Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 有關聯席公司秘書資格的更新 茲提述醫渡科技有限公司（「本公司」，連同其附屬公司，統稱「本集團」）日期為2023 年2月1日之公告（「該公告」），內容有關（其中包括）委任封曉瑛女士（「封女士」）為本 公司之聯席公司秘書，自2023年2月1日起生效。 誠如該公告所述，香港聯合交易所有限公司（「聯交所」）已向本公司就封女士擔任本 公司聯席公司秘書的資格 ...

相关事件 医渡科技(02158.HK)2月3日耗资821.8万港元回购146.3万股 医渡科技(02158.HK)2月2日耗资499.8万港元 回购88.5万股 格隆汇2月3日丨医渡科技(02158.HK)公告，2月3日耗资821.8万港元回购146.3万股。 ...

Group 1 - The core viewpoint of the article highlights that Yidu Tech (02158) has demonstrated a strong commitment to share buybacks, with a recent purchase of over 1.46 million shares at approximately HKD 5.6 per share, totaling over HKD 8 million, marking a new high for daily buyback amounts [1] - As of February 3, Yidu Tech has executed share buybacks for seven consecutive trading days, accumulating a total buyback amount exceeding HKD 22.7 million, indicating a robust strategy to enhance market confidence [1] - Huajin Securities reports that AI technology is increasingly penetrating the entire healthcare industry chain, significantly improving the efficiency and quality of medical services, with supportive policies from various government departments promoting AI applications in healthcare [1] Group 2 - Yidu Tech, as a veteran in AI healthcare, is steadily advancing its business, recently implementing innovative systems for diagnostic assistance and health management in cities like Chongqing and Shenzhen [1] - Market analysis suggests that the continuous share buyback operations, combined with signals of fundamental improvement and progress in diverse business areas, reinforce market perceptions of the company's strategic execution efficiency and long-term investment value [1]

Group 1 - The core viewpoint of the article highlights that Yidu Tech (02158) has demonstrated a strong commitment to boosting market confidence through significant share buybacks, with over 1.46 million shares repurchased at approximately HKD 5.6 per share, totaling over HKD 8 million on February 3 [1] - As of February 3, Yidu Tech has executed share buybacks for seven consecutive trading days, accumulating a total buyback amount exceeding HKD 22.7 million [1] - Huajin Securities reports that AI technology is increasingly penetrating the entire healthcare industry chain, enhancing efficiency and quality across drug development, clinical trials, and treatment processes, supported by government policies promoting AI applications in healthcare [1] Group 2 - Yidu Tech, as a veteran player in AI healthcare, is making steady progress in its business, recently implementing innovative diagnostic assistants and health management systems in cities like Chongqing and Shenzhen [1] - Market analysis suggests that the continuous share buyback operations, combined with signals of fundamental improvement and progress in diverse business areas, reinforce market perceptions of the company's strategic execution efficiency and long-term investment value [1]

智通财经APP讯，医渡科技(02158)公布，2026年2月3日耗资约821.79万港元回购146.28万股股份。 ...

医渡科技(02158)公布，2026年2月3日耗资约821.79万港元回购146.28万股股份。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月3日 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 ...

Group 1 - The core point of the news is that Yidu Tech (02158) has been actively repurchasing its shares, with a recent buyback of over 880,000 shares at approximately HKD 5.65 per share, totaling around HKD 5 million, marking a new high for single-day repurchase amounts [1] - The company has conducted share buybacks for six consecutive trading days, with a cumulative repurchase amount nearing HKD 15 million, indicating a strong commitment to its buyback plan and confidence in its intrinsic value and long-term growth prospects [1] - The ongoing buyback activity is supported by the steady progress of Yidu Tech's AI healthcare business and the enhancement of its core competitiveness, highlighted by a strategic partnership with Nanshan People's Hospital in Shenzhen to develop an "AI + health management" system [1] Group 2 - Recent business achievements include surpassing 4.5 million insured individuals in the 2026 Beijing Universal Health Insurance project, demonstrating the company's strong capabilities in the healthcare service sector [2] - The launch of the "General Medicine Diagnosis AI Assistant" in collaboration with Chongqing Medical University First Affiliated Hospital has been trialed in over 20 grassroots medical institutions in Chongqing, creating a replicable digital healthcare solution [2] - Industry experts view the company's share repurchase as a positive signal for investors, reflecting confidence in profitability growth and quality improvement, which can help maintain the company's value and enhance investor expectations for future development [2]

医渡科技(02158)发布公告，于2026年2月2日斥资499.84万港元回购88.54万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月2日斥资499.84万港元回购88.54万股。 ...